Inogen (NASDAQ:INGN) Shares Cross Above Fifty Day Moving Average - Here's Why

Key Points

• Inogen's share price recently passed above its 50-day moving average of $6.93, trading as high as $7.74 before closing at $7.71.
• Analyst ratings for Inogen vary; B. Riley rates it a "buy" with a price target of $14, while Stifel Nicolaus has cut its price target from $10 to $7 with a "hold" rating.
• Inogen reported a revenue of $92.28 million in its latest quarterly earnings, exceeding the consensus estimate and beating EPS predictions by $0.07.

Shares of Inogen, Inc (NASDAQ:INGN - Get Free Report) passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $6.93 and traded as high as $7.74. Inogen shares last traded at $7.71, with a volume of 154,207 shares.

Analyst Ratings Changes

Several analysts have commented on INGN shares. Stifel Nicolaus decreased their price target on shares of Inogen from $10.00 to $7.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th. Needham & Company LLC upgraded shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price target on the stock in a research note on Thursday, May 22nd. Finally, B. Riley initiated coverage on shares of Inogen in a research report on Monday, June 16th. They set a "buy" rating and a $14.00 target price on the stock. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $11.00.

Inogen Trading Up 0.4%

The stock has a market capitalization of $216.05 million, a PE ratio of -7.54 and a beta of 1.72. The firm's 50-day moving average price is $7.04 and its 200-day moving average price is $7.19.

Inogen (NASDAQ:INGN - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical technology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.07. The company had revenue of $92.28 million for the quarter, compared to the consensus estimate of $90.40 million. Inogen had a negative net margin of 7.58% and a negative return on equity of 13.77%. Inogen has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts predict that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inogen

Several hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its holdings in Inogen by 5.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 26,710 shares of the medical technology company's stock valued at $245,000 after purchasing an additional 1,318 shares during the last quarter. Invesco Ltd. grew its stake in Inogen by 2.0% in the 4th quarter. Invesco Ltd. now owns 78,142 shares of the medical technology company's stock worth $717,000 after acquiring an additional 1,545 shares in the last quarter. CWM LLC grew its stake in Inogen by 11.0% in the 2nd quarter. CWM LLC now owns 16,258 shares of the medical technology company's stock worth $114,000 after acquiring an additional 1,611 shares in the last quarter. Cubist Systematic Strategies LLC grew its stake in Inogen by 1.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 124,993 shares of the medical technology company's stock worth $891,000 after acquiring an additional 1,751 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Inogen by 7.0% in the 2nd quarter. Rhumbline Advisers now owns 39,059 shares of the medical technology company's stock worth $275,000 after acquiring an additional 2,561 shares in the last quarter. 89.94% of the stock is currently owned by institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.